The United Kingdom and the United States have finalized a important commercial pact that will maintain zero import taxes on UK drug shipments going into the American market.
Agreement Details of the Pact
In exchange for the tariff guarantee, the UK has committed to increase funding on drugs through the National Health Service (NHS). This commitment ensures that duties on these vital products will remain at zero for a period of 36 months.
This development follows recent warnings to dramatically increase duties on patented drug products, with figures discussed up to one hundred percent.
"This agreement with the UK bolsters the worldwide climate for new treatments and introduces much-needed balance to U.S.–U.K. pharmaceutical trade," a release said.
Economic Impact
Medicines represent one of the Britain's most significant export categories to the United States, which is by far the biggest destination for leading UK drugmakers.
Trade data indicate that in the one-year period leading up to September, the UK exported medicines totaling billions to the US. This value accounted for nearly one-fifth of British export trade in that span.
"This guarantee protects jobs, stimulates investment and sets the stage for the UK to establish itself as a international leader for life sciences," a government official stated.
Key NHS Changes
The deal involves several specific commitments from the United Kingdom:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new medicines to be prohibitively costly by 25%.
- Boosted Medicine Funding: There is a goal to double total NHS spending on treatments from 0.3 percent of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The sum pharmaceutical firms must pay back to the NHS to control costs will be restricted at fifteen percent. In the past, rebates were more than 20%.
Recent Tensions
The deal takes place against a ongoing dispute between the drug companies and the UK government over drug pricing and approval rates.
This friction were intensified by claims that US consumers were paying a premium for the same drugs than people in the Britain and the EU.
Recently, several major pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar investments have been announced toward American operations.
One official acknowledged that the NHS must increase expenditure on drugs, noting that its spending on drugs had shrunk as a share of its overall budget over the previous ten-year period.
